Pulmonary Drug Delivery Systems Market is expected to reach US$ 73.14 billion by 2031

Dry Powder Inhalers Segment, Based on Product, to Lead Pulmonary Drug Delivery Systems Market During 2023–2031

According to our new research study on “Pulmonary Drug Delivery Systems Market Forecast to 2031 – Global Analysis – by Product, Indication, Distribution Channel, End User, and Geography,” the market was valued at US$ 49.71 billion in 2023 and is projected to reach US$ 73.14 billion by 2031; it is expected to register a CAGR of 4.9% from 2023 to 2031. The increasing burden of respiratory diseases and growing strategic initiatives by companies drive market growth. However, regulatory issues associated with the approval of pulmonary drug delivery systems hinder the growth of the pulmonary drug delivery systems market.

Pulmonary Drug Delivery Systems Market Analysis Based on Segmental Evaluation

The market, based on product, is segmented into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment held a significant pulmonary drug delivery systems market share in 2023. The segment is estimated to register the highest CAGR during the forecast period. Unlike other inhalers, which deliver a puff of medicine, dry powder inhalers (DPIs) hold the medicine as a dry powder. Since the medicine sits inside as a powder, the patient needs to breathe quickly and deeply to get the medicine into the lungs. DPIs contain a powder formulation, which most frequently consists of an ordered mixture of micronized drugs (<5 μm in diameter) and larger carrier lactose particles that are required to improve powder flow properties. The patient's inhalation through the device is used to disperse the powder and ensure that some of the dose is carried into the lungs. Dry powder inhalers are clinically appropriate and cost-effective alternatives, positively influencing the pulmonary drug delivery systems market growth.

Pulmonary Drug Delivery Systems Market, by Region, 2023(%)

Source: The Insight Partners Analysis

Based on indication, the market is segmented into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The chronic obstructive pulmonary diseases segment held a significant pulmonary drug delivery systems market share in 2023. The same segment is expected to record the highest CAGR during 2023–2031.

The scope of the pulmonary drug delivery systems market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is likely to register the highest CAGR in the market from 2023 to 2031. The rising geriatric population, increasing incidence of respiratory diseases, developing healthcare infrastructure, and growing investments in the development of innovative pulmonary drug delivery system products and solutions are projected to support the pulmonary drug delivery systems market growth in Asia Pacific during the forecast period. China and Japan are the main contributors to the market growth in the region. The increasing geriatric population is one of the major reasons for the growth of the healthcare industry in Japan. According to data from World bank, the share of the geriatric population in Japan was about 28.4% in 2020. As per the Statistics Bureau of Japan, the number of older people aged 65 and above accounted for 28.9% of the total 36.21 million population in 2021. As per the National Institute of Population and Social Security Research, Population Projections for Japan: 2015–2065, 37.7% of the Japanese population will be 65 years and above by 2050.

According to a recent study, “Chronic Illness and Ageing in China,” published in 2020, China's population is aging, and chronic illnesses are increasingly prevalent. From 2010 to 2040, it is estimated that the proportion of people aged 60 years and above in China will rise from 12.4% (168 million) to 28% (402 million). In the country, about 80% of deaths in people aged 60 years are caused due to chronic noncommunicable diseases, the most prevalent diseases being stroke, ischemic heart disease, chronic obstructive pulmonary disease (COPD), and type 2 diabetes. A global increase in the elderly population, who are prone to respiratory illnesses, presents a growing market for pulmonary drug delivery devices. These systems are easy to use for patients with limited dexterity or cognitive function and help to meet a critical need in this age group. Therefore, increasing geriatric population is expected to contribute to the growing pulmonary drug delivery systems market size.

Furthermore, asthma is a major public health concern in China, and it affects millions of people. According to a study, “Long-Term Trends of Asthma Mortality in China from 2000 to 2019,” published in the National Library of Medicine in 2022, the prevalence of asthma was 4.2%, representing 45.7 million people, in the country in 2019. According to the World Health Organization 2023 data, ~100 million people are affected by COPD in China, which accounts for about 25% of all COPD cases across the world. As per the “Narrative review of current COPD status in Japan,” published in the National Library of Medicine in 2021, ~6 million people in Japan are suffering from COPD, and the country reports 60,000 deaths due to COPD annually. Therefore, the growing burden of respiratory diseases in the Asia Pacific region supports the market growth. Moreover, advancements in inhaler technologies are projected to bring new pulmonary drug delivery systems market trends in the coming years.

AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies are among the leading companies profiled in the pulmonary drug delivery systems market report.

Based on product, the pulmonary drug delivery systems market is segmented into dry powder inhalers, metered dose inhalers, and nebulizers. In terms of indication, the market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. In terms of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. Based on end user, the market is bifurcated into hospitals & clinics and homecare. Geographically, the pulmonary drug delivery systems market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com